Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Drops By 14.8%

TScan Therapeutics, Inc. (NASDAQ:TCRX) was the recipient of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 1,900,000 shares, a decline of 14.8% from the February 28th total of 2,230,000 shares. Currently, 4.4% of the shares of the company are sold short. Based on an average trading volume of 433,800 shares, the short-interest ratio is presently 4.4 days.

TScan Therapeutics Price Performance

Shares of TCRX stock opened at $1.38 on Tuesday. The stock’s fifty day simple moving average is $2.02 and its 200 day simple moving average is $3.53. TScan Therapeutics has a one year low of $1.28 and a one year high of $9.69. The firm has a market cap of $78.10 million, a price-to-earnings ratio of -1.30 and a beta of 0.91. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $0.67 million during the quarter, compared to analyst estimates of $1.43 million. On average, analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

Several institutional investors have recently added to or reduced their stakes in TCRX. Stifel Financial Corp increased its holdings in shares of TScan Therapeutics by 3.9% during the third quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock worth $494,000 after buying an additional 3,733 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of TScan Therapeutics by 31.2% in the 4th quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock worth $62,000 after acquiring an additional 4,852 shares in the last quarter. Wells Fargo & Company MN grew its position in TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock worth $59,000 after acquiring an additional 5,694 shares during the last quarter. Wellington Management Group LLP increased its holdings in TScan Therapeutics by 5.2% during the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock valued at $404,000 after purchasing an additional 6,550 shares in the last quarter. Finally, Woodline Partners LP raised its position in TScan Therapeutics by 6.7% in the 4th quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock valued at $352,000 after purchasing an additional 7,282 shares during the last quarter. 82.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on TCRX shares. Wedbush reiterated an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a research report on Wednesday, March 5th. Barclays reduced their target price on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Morgan Stanley reiterated an “overweight” rating and set a $10.00 price target on shares of TScan Therapeutics in a research note on Friday, March 14th. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research note on Thursday, March 6th. Finally, Needham & Company LLC decreased their target price on shares of TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, TScan Therapeutics has a consensus rating of “Buy” and a consensus target price of $9.33.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.